Logo image of KYTX

KYVERNA THERAPEUTICS INC (KYTX) Stock Fundamental Analysis

NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD

4.03  +0.46 (+12.89%)

After market: 4.12 +0.09 (+2.23%)

Fundamental Rating

1

Taking everything into account, KYTX scores 1 out of 10 in our fundamental rating. KYTX was compared to 557 industry peers in the Biotechnology industry. The financial health of KYTX is average, but there are quite some concerns on its profitability. KYTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KYTX had negative earnings in the past year.
KYTX had a negative operating cash flow in the past year.
KYTX Yearly Net Income VS EBIT VS OCF VS FCFKYTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -55.87%, KYTX perfoms like the industry average, outperforming 45.78% of the companies in the same industry.
With a Return On Equity value of -65.00%, KYTX perfoms like the industry average, outperforming 58.17% of the companies in the same industry.
Industry RankSector Rank
ROA -55.87%
ROE -65%
ROIC N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYTX Yearly ROA, ROE, ROICKYTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

KYTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYTX Yearly Profit, Operating, Gross MarginsKYTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for KYTX has been increased compared to 1 year ago.
The debt/assets ratio for KYTX has been reduced compared to a year ago.
KYTX Yearly Shares OutstandingKYTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
KYTX Yearly Total Debt VS Total AssetsKYTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.17, we must say that KYTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.17, KYTX is in the better half of the industry, outperforming 60.68% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that KYTX is not too dependend on debt financing.
The Debt to Equity ratio of KYTX (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.17
ROIC/WACCN/A
WACCN/A
KYTX Yearly LT Debt VS Equity VS FCFKYTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

KYTX has a Current Ratio of 7.44. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.44, KYTX is in the better half of the industry, outperforming 68.04% of the companies in the same industry.
A Quick Ratio of 7.44 indicates that KYTX has no problem at all paying its short term obligations.
The Quick ratio of KYTX (7.44) is better than 68.58% of its industry peers.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
KYTX Yearly Current Assets VS Current LiabilitesKYTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

KYTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.84%.
EPS 1Y (TTM)-137.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KYTX will show a small growth in Earnings Per Share. The EPS will grow by 0.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.05%
EPS Next 2Y2.23%
EPS Next 3Y-7.6%
EPS Next 5Y0.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KYTX Yearly Revenue VS EstimatesKYTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KYTX Yearly EPS VS EstimatesKYTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KYTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYTX Price Earnings VS Forward Price EarningsKYTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYTX Per share dataKYTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

KYTX's earnings are expected to decrease with -7.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.23%
EPS Next 3Y-7.6%

More info and screens

0

5. Dividend

5.1 Amount

KYTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYVERNA THERAPEUTICS INC

NASDAQ:KYTX (7/11/2025, 8:00:02 PM)

After market: 4.12 +0.09 (+2.23%)

4.03

+0.46 (+12.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners78.05%
Inst Owner Change0.16%
Ins Owners1.39%
Ins Owner Change2.82%
Market Cap174.18M
Analysts83.33
Price Target17.54 (335.24%)
Short Float %4.97%
Short Ratio4.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.17%
Min EPS beat(2)-2.95%
Max EPS beat(2)9.3%
EPS beat(4)3
Avg EPS beat(4)3.19%
Min EPS beat(4)-2.95%
Max EPS beat(4)9.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.18%
PT rev (3m)-1.15%
EPS NQ rev (1m)4.57%
EPS NQ rev (3m)-10.6%
EPS NY rev (1m)0.39%
EPS NY rev (3m)-3.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.08
OCFYN/A
SpS0
BVpS5.18
TBVpS5.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.87%
ROE -65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.44
Quick Ratio 7.44
Altman-Z -0.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
EPS Next Y-14.05%
EPS Next 2Y2.23%
EPS Next 3Y-7.6%
EPS Next 5Y0.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-129.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.27%
EBIT Next 3Y-25.97%
EBIT Next 5YN/A
FCF growth 1Y-119.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.99%
OCF growth 3YN/A
OCF growth 5YN/A